Sign in

CIK 0001819133

  • Non-accelerated filer
  • Smaller reporting company

Tango Therapeutics, Inc.

Sign in to watch
Ticker
TNGX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
Phone
+1 857-320-4900
Business address
201 BROOKLINE AVENUE, SUITE 901, BOSTON, MA, 02215
Former names
BCTG Acquisition Corp.
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$1,858,086
in 6 filings, $1.9M under 10b5-1 plans

Net −$1,858,086. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Reading 18 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2026-11-11 Crystal Adam President, R&D Option exercise 10b5-1 +5,000 $2.91 $15K 120,743
2026-11-11 Crystal Adam President, R&D Sale 10b5-1 −5,000 $25.00 $125K 115,743
2026-11-11 Crystal Adam President, R&D Option exercise · Stock Option (Right to Buy) 10b5-1 −5,000 308,090
2026-11-02 Crystal Adam President, R&D Option exercise 10b5-1 +5,000 $2.91 $15K 120,743
2026-11-02 Crystal Adam President, R&D Sale 10b5-1 −3,900 $22.26 $87K 116,843
2026-11-02 Crystal Adam President, R&D Sale 10b5-1 −1,100 $22.99 $25K 115,743
2026-11-02 Crystal Adam President, R&D Option exercise · Stock Option (Right to Buy) 10b5-1 −5,000 313,090
2026-10-01 Crystal Adam President, R&D Option exercise 10b5-1 +27,000 $5.20 $140K 142,743
2026-10-01 Crystal Adam President, R&D Sale 10b5-1 −26,400 $24.45 $646K 116,343
2026-10-01 Crystal Adam President, R&D Sale 10b5-1 −600 $25.32 $15K 115,743
2026-10-01 Crystal Adam President, R&D Option exercise · Stock Option (Right to Buy) 10b5-1 −27,000 233,040
2026-09-01 Crystal Adam President, R&D Option exercise 10b5-1 +27,000 $5.20 $140K 142,743
2026-09-01 Crystal Adam President, R&D Sale 10b5-1 −27,000 $22.37 $604K 115,743
2026-09-01 Crystal Adam President, R&D Option exercise · Stock Option (Right to Buy) 10b5-1 −27,000 260,040
2026-08-03 Crystal Adam President, R&D Option exercise 10b5-1 +27,000 $5.20 $140K 142,743
2026-08-03 Crystal Adam President, R&D Sale 10b5-1 −5,267 $26.79 $141K 137,476
2026-08-03 Crystal Adam President, R&D Sale 10b5-1 −21,733 $27.35 $594K 115,743
2026-08-03 Crystal Adam President, R&D Option exercise · Stock Option (Right to Buy) 10b5-1 −27,000 287,040
2026-07-01 Crystal Adam President, R&D Option exercise 10b5-1 +27,000 $5.20 $140K 142,743
2026-07-01 Crystal Adam President, R&D Sale 10b5-1 −19,629 $29.34 $576K 123,114

Page 1 of 3 · 56 trades